Phase 2 N=17 Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
Bladder Cancer
Primary: Arm A: Progression Free Survival (PFS) — 8 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=45 Effect of Miswak and Miswak Extract on Oral Malodor
Oral Malodor · Halitosis
Primary: Organoleptic Scores After the First Use of the Prescribed Method by 15 Minutes (Masking Effect), and After 7 Days of Use (Therapeutic Effect). — 2.10; 1.62; 1.36; 1.10…
Phase 2 N=164 Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
Prostate Cancer
Primary: Percentage of Participants Experiencing Neither of the 2 Mineralocorticoid Excess Toxicity During the First 24 Weeks of Treatment — 70.6; 36.8; 60.0; 70.3 Percentage of…
Phase 2 N=10 Oral Nadolol for the Treatment of Adults With Mild Asthma
Asthma
Primary: Mean Daily Dose at Study Termination Across Participants — 29.6 mg
Phase 2 N=120 Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
Metastatic Breast Cancer
Primary: Number of Participants With Clinical Benefit (CBR) and Number of Participants With CBR Having a Disease Free Interval (DFI) Greater Than 2 Years - Evaluable Population…
Phase 2 N=17 A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
Hemophilia B
Primary: Number of Subjects With Treatment-related Adverse Events — 0 participants
Phase 2 N=8 Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency
Cholesterol Ester Storage Disease (CESD) · Lysosomal Acid Lipase Deficiency · LAL-Deficiency
Primary: Number Of Participants Reporting TEAEs And IARs — 8; 1; 2; 0 Participants
Phase 2 N=68 OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
Chronic Allergic Conjunctivitis
Primary: Ocular Itching — 1.80; 2.58; 1.72; 2.70 units on a scale (0 -4)
Phase 2 N=18 The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
Kidney Transplantation
Primary: Response to Bortezomib Monotherapy — 0; 0; 0; 1 participants
Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
Phase 2 N=450 PATH Partnering to Achieve Tobacco-free Health
Smoking Cessation
Primary: Number of Participants Who Stopped Smoking by 12 Month Post Treatment — 31; 41 participants
Phase 2 N=8 Bortezomib in Treating Patients With Myelodysplastic Syndromes
Myelodysplastic Syndromes
Primary: Number of Participants Who Experienced an Adverse Event — 6 participants
Phase 2 N=60 Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome
Leukemia
Primary: Phase I: Maximum Tolerated Dose (MTD) of Sorafenib Given With Azacitidine — 400 mg/twice daily
Phase 2 N=32 Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Uterine Hemorrhage · Contraception
Primary: Cessation of Vaginal Bleeding — 37.5; 87.5 percentage of participants
Phase 2 N=167 A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
Squamous Non Small Cell Lung Cancer
Primary: Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Response Rates [ORR]) — 48.9; 40.0…